Why retatrutide isn’t legally available in the UK yet
Retatrutide is an investigational medicine made by Eli Lilly.
It’s a triple-action medication that mimics the effects of the hormones GLP-1, GIP, and glucagon. The Phase 3 TRIUMPH programme is still running.
The first Phase 3 trial to report results, TRIUMPH-4, was published on 11 December 2025.
It found 28.7% body-weight loss at 68 weeks on the 12 mg dose, alongside reduced knee osteoarthritis pain.4
Eli Lilly has said it expects to file for regulatory approval once the remaining TRIUMPH trials report results in 2026, and UK approval would follow shortly after.
The realistic UK timeline
For a medicine to be legally prescribed in the UK, it needs a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA).
For NHS access, NICE then has to recommend it through a technology appraisal.
As a comparison, Wegovy received MHRA approval in September 2021, with NICE TA875 following in March 2023.5
Mounjaro received MHRA approval for weight management in November 2023, with NICE TA1026 following in December 2024.6
If retatrutide follows the same pattern, we would expect an Eli Lilly regulatory filing late in 2026, MHRA approval in late 2027 to mid 2028, and NHS access via NICE from 2029 at the earliest.
Until that authorisation is in place, no UK pharmacy or licensed clinic can supply retatrutide.
The medicines.org.uk database has no SmPC for retatrutide because no UK SmPC exists.
Where online retatrutide actually comes from
The ‘retatrutide pens’ sold online come from three main sources, none of which go through the MHRA.
First, peptide labs and ‘research chemical’ vendors, mostly outside the UK and EU, that ship unlicensed retatrutide vials labelled ‘not for human consumption’ to dodge medicines law.2
Second, illicit manufacturing operations produce counterfeit pens designed to look like prescription medicines. The MHRA has identified at least two of these in the UK alone.1,3
Third, online pharmacies that present themselves as legitimate but operate without UK pharmacy licensing or valid prescription requirements.
The U.S. National Association of Boards of Pharmacy (NABP) has documented this pattern internationally, including websites that mimic legitimate sellers, mislabelling products as ‘peptides for research purposes only’, and non-delivery scams in which customers pay but receive nothing.²
None of these routes goes through the MHRA. That means no purity testing, no dose accuracy verification, no manufacturing standards, and no recourse if something goes wrong.
MHRA enforcement and counterfeits
On 24 October 2025, the MHRA carried out what it described as a record seizure at a warehouse on the outskirts of Northampton.1
Officers recovered more than 2,000 unlicensed retatrutide and tirzepatide pens awaiting dispatch to customers, plus tens of thousands of empty pens ready to be filled, raw chemical ingredients, and packaging equipment.1
Andy Morling, head of the MHRA’s Criminal Enforcement Unit, called it ‘a landmark result’ and ‘a major blow to the illegal trade’.1
Less than four months later, on 25 February 2026, the MHRA disrupted a second site, this one operating across a farm near Sleaford and a residential address in Grantham.3
Officers seized almost 2,000 doses of unauthorised weight-loss medicines, including retatrutide and tirzepatide, alongside manufacturing equipment and pharmaceutical ingredients.3
The NABP’s 2024 RogueRx report on injectable weight-loss drugs documented criminal networks selling counterfeit GLP-1 medicines online, often by mimicking legitimate websites or labelling the product as ‘peptides for research purposes only’ to evade enforcement.2
Demand for retatrutide is high enough that counterfeit operations are profitable. A pen that costs the buyer £100 might contain anything, or nothing.
Specific risks of unlicensed retatrutide
Contaminated or substandard product
The NABP’s RogueRx report documents how illegal online sellers operate without pharmacy licensing, valid prescriptions, or quality oversight, and how counterfeit GLP-1 medicines have been distributed internationally through these channels.²
Without MHRA-equivalent quality control, what’s in the vial isn’t guaranteed to match the label.
The MHRA has separately reported that counterfeit pens have been found to contain insulin or unidentified substances, which can cause life-threatening low blood sugar in people who don’t have diabetes.
Wrong dose strength
Retatrutide is potent. Phase 3 doses are titrated up gradually to a maximum of 12 mg per week.4
A vial labelled at one dose that actually contains a much higher dose can produce severe nausea, vomiting, dehydration, or worse, as there’s no regulator checking.
Unverified contents
Counterfeit pens have been found to contain insulin, saline, or unidentified peptides.
Substituting one peptide for another can be dangerous, particularly if the buyer thinks they’re injecting something with one safety profile and is actually receiving another.
No clinical oversight
Real prescribing involves screening for whether the medication is safe for you, given your medical history, and monitoring during dose increases.
Buying online means you’re managing a highly potent medicine on your own.
If you develop pancreatitis, severe hypoglycaemia, or arrhythmia, there’s no clinician who knows what you’re on.
No recall route if there’s a problem
If a regulated medicine is found to be contaminated, the MHRA can recall the batch and contact prescribers.
Counterfeit and grey-market products lack batch tracking and a recall mechanism.
What people online are doing, and why it’s risky
Online communities describe people sourcing unlicensed retatrutide from offshore vendors and self-administering it over a period of time.
The protocols vary, none are clinically supervised, and the outcomes reported by users include both the weight loss seen in trials and the side effects.
Some users report fast weight loss after switching from Wegovy or Mounjaro.
They also report a familiar list of issues that prescribers see in trials: severe nausea during titration, persistent fatigue, raised heart rate, and a ‘burning’ skin sensation that researchers call dysesthesia.7
The harder problems are the ones that don’t show up in user reports. Mixing errors when preparing the injection can lead to people taking far too much or far too little.
Storing the medication incorrectly in a domestic fridge can degrade it.
There’s no way to tell whether a non-response is the product, the dose, or individual variability, and no clinician to call when something goes wrong.
What the trials show on safety
Retatrutide isn’t a benign drug. It’s a high-potency medication with a safety profile that’s still being outlined. Trials have flagged signals to monitor.
Heart rate increase
Phase 2 data showed a mean heart rate increase of around 6.7 beats per minute on the 12 mg dose, peaking at about week 24 and declining slightly thereafter.7
Cardiac arrhythmias
Phase 2 reported cardiac arrhythmia rates of 2 to 11% with retatrutide, compared with 2% with placebo.7
No major adverse cardiovascular events have been reported to date, but a dedicated cardiovascular outcomes trial is still pending.
Dysesthesia
A skin sensitivity or ‘burning’ sensation has been flagged as a signal to monitor in Phase 3. Its mechanism isn’t fully understood.
The same signal has been observed at high rates with Wegovy 7.2 mg, suggesting it’s an effect in the higher doses of GLP-1 medications rather than something specific to retatrutide.
Gastrointestinal side effects
Nausea is dose-dependent, ranging from approximately 14% at 1 mg to 60% at 12 mg, mostly during titration.7
In a clinical trial, a prescriber can slow dose increases or adjust the dose if side effects impact your quality of life, which isn’t an option when buying online.
Without a prescriber managing the dose increases and monitoring for side effects, the same drug that produces 28.7% weight loss in trials becomes harder to use safely.
What to do instead: MHRA-approved options
Two GLP-1 weight-loss medications are currently approved by the MHRA and recommended by NICE for use in eligible adults: Mounjaro (tirzepatide) and Wegovy (semaglutide).
| Medication |
UK approval |
Average weight loss in trials |
How to access |
| Mounjaro (tirzepatide) |
MHRA approved Nov 2023; NICE TA1026 Dec 20246 |
Around 22.5% at 72 weeks on the 15 mg dose (SURMOUNT-1) |
UK pharmacy with prescription; NHS specialist services; private programmes |
| Wegovy (semaglutide) |
MHRA approved Sep 2021; NICE TA875 Mar 20235 |
Around 14.9% at 68 weeks (STEP 1) |
UK pharmacy with prescription; NHS specialist services; private programmes |
| Retatrutide |
No UK approval; Phase 3 ongoing |
28.7% at 68 weeks on 12 mg dose (TRIUMPH-4)4 |
Not legally available in the UK in 2026 |
Frequently asked questions
Is retatrutide legal in the UK?
Retatrutide isn’t approved by the MHRA, which means there’s no legal route to be prescribed or supplied retatrutide in the UK in 2026.1
Selling it as a medicine without authorisation is a criminal offence under UK medicines law.
Can you buy retatrutide on the NHS?
No. The NHS can only prescribe medicines that have a UK marketing authorisation and have been recommended by NICE.
Retatrutide has neither yet. NHS access is likely to be available from 2029 at the earliest, and only if NICE finds it cost-effective.
When will retatrutide be available in the UK?
Eli Lilly is expected to file for regulatory approval after the TRIUMPH Phase 3 trials are published in 2026.
Based on the Wegovy and Mounjaro timelines, MHRA approval is realistic in late 2027 to mid 2028, with NICE recommendation following 6 to 18 months later.5,6
Is buying retatrutide online safe?
No. Online sellers are operating outside MHRA oversight. The MHRA has raided two UK manufacturing sites producing counterfeit retatrutide and tirzepatide in the last seven months.1,3
Counterfeit products may contain the wrong dose, the wrong drug entirely, or contaminants.
Are retatrutide pens real?
Real Eli Lilly retatrutide pens exist only inside Phase 3 clinical trials.
Any pen you can buy online in 2026 isn’t from Eli Lilly’s commercial supply because there isn’t one yet.
It’s either an unlicensed peptide, a counterfeit, or, in some cases, a non-delivery scam.2
What’s the difference between retatrutide and Mounjaro?
Mounjaro (tirzepatide) mimics two hormones, GLP-1 and GIP. Retatrutide mimics three, also mimicking glucagon.
Phase 3 retatrutide trials suggest higher weight loss with the 12 mg dose (28.7% in TRIUMPH-4) than with Mounjaro at its 15 mg dose (around 22.5% in SURMOUNT-1).4
Mounjaro is approved and available in the UK; retatrutide isn’t.
Can my GP prescribe retatrutide?
No. GPs can only prescribe medicines licensed by the MHRA. Retatrutide doesn’t have a UK licence, so no UK clinician, GP or otherwise, can lawfully prescribe it.
What should I do if I’ve already bought retatrutide online?
If you haven’t used it, don’t start. If you have, stop using it and book a GP appointment.
Tell your GP what you took, the dose, and any symptoms.
Don’t combine unlicensed retatrutide with a prescribed GLP-1 medication.
If you experience severe abdominal pain, persistent vomiting, signs of pancreatitis, or new heart rhythm symptoms, contact NHS 111 or A&E.
How do I know if a weight-loss injection is genuine?
Genuine Mounjaro and Wegovy are dispensed by UK-registered pharmacies against a valid prescription, with a UK SmPC listed on medicines.org.uk and batch information traceable through the supply chain.
Anything sold without a prescription, marketed as a ‘peptide’ or ‘research chemical’, or dispatched from an offshore site is not a regulated UK medicine.2
Take home message
Retatrutide isn’t legally available in the UK in 2026. The Phase 3 TRIUMPH programme is still running, and MHRA approval is realistic in late 2027 to mid 2028, with NHS access from 2029 at the earliest.
Online retatrutide isn’t a real Eli Lilly product. It’s unlicensed peptide stock, counterfeit pens, or both.
The MHRA has raided two UK manufacturing sites in seven months and seized thousands of fake retatrutide and tirzepatide pens.
The risks of buying online include contaminated or substandard products, wrong-dose pens, unverified contents, no clinical oversight during titration, and no recall route if a batch is found to be unsafe.
If you’re considering weight-loss medication now, the regulated alternatives are Mounjaro and Wegovy.
Both are MHRA-approved, NICE-recommended, and available through UK clinicians and licensed programmes.
Second Nature’s programme combines MHRA-approved medication with personalised nutrition guidance from registered dietitians and nutritionists.
A peer-reviewed study in JMIR Formative Research found that active subscribers lost an average of 19.1% of their body weight at 12 months, with 77.7% achieving at least 10% weight loss.8
If you’ve already bought retatrutide online, see your GP. Don’t combine it with a prescribed GLP-1, and don’t keep using it.
Second Nature's Mounjaro and Wegovy programmes
Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes.
Why choose Second Nature over other medication providers, assuming you're eligible?
Because peace of mind matters.
We've had the privilege of working with the NHS for over eight years, helping people across the UK take meaningful steps toward a healthier, happier life.
Our programmes are designed to meet people where they are, whether that means support with weight loss through compassionate one-to-one health coaching, or access to the latest weight-loss medications (like Mounjaro and Wegovy) delivered alongside expert care from a multidisciplinary team of doctors, psychologists, dietitians, and personal trainers.
At the heart of everything we do is a simple belief: real, lasting change comes from building better habits, not relying on quick fixes. We're here to support that change every step of the way.
With over a decade of experience, thousands of lives changed, and a long-standing record of delivering programmes used by the NHS, we believe we're the UK's most trusted weight-loss programme.
We hope to offer you something invaluable: peace of mind, and the support you need to take that first step.
References
- Medicines and Healthcare products Regulatory Agency. (2025). MHRA smashes major illicit weight loss medicine production facility in record seizure. GOV.UK news release, 24 October 2025.
- National Association of Boards of Pharmacy. (2024). Injectable Weight Loss Drugs: How Illegal Online Drug Sellers Are Taking Advantage of Patients. RogueRx Activity Report.
- Medicines and Healthcare products Regulatory Agency. (2026). MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicines. GOV.UK news release, 25 February 2026.
- Eli Lilly and Company. (2025). Lilly’s triple agonist retatrutide delivered weight loss of an average of 28.7% in TRIUMPH-4. Press release, 11 December 2025.
- National Institute for Health and Care Excellence. (2023). TA875: Semaglutide for managing overweight and obesity.
- National Institute for Health and Care Excellence. (2024). TA1026: Tirzepatide for managing overweight and obesity.
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. A Phase 2 Trial. New England Journal of Medicine, 389(6), 514-526.
- Richards, R., et al. (2025). A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation. JMIR Formative Research.
